H.C. Wainwright raised the firm’s price target on Ovid Therapeutics (OVID) to $2 from $1.50 and keeps a Buy rating on the shares. OV329’s initial clinical data show robust safety and position the compound favorably for proof-of-concept clinical development, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OVID:
- Leerink bullish on Ovid Therapeutics, initiates with an Outperform
- Ovid Therapeutics initiated with an Outperform at Leerink
- Ovid Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
- Ovid Therapeutics Reports Q3 2025 Financial Results
- Ovid Therapeutics reports Q3 EPS (17c), consensus (15c)